Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection
© 2023 The Author(s)..
Background: Pregnancy is associated with a higher risk of adverse symptoms and outcomes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for both mother and neonate. Antibodies can provide protection against SARS-CoV-2 infection and are induced in pregnant women after vaccination or infection. Passive transfer of these antibodies from mother to fetus in utero may provide protection to the neonate against infection. However, it is unclear whether the magnitude or quality and kinetics of maternally derived fetal antibodies differs in the context of maternal infection or vaccination.
Objective: We aimed to determine whether antibodies transferred from maternal to fetus differed in quality or quantity between infection- or vaccination-induced humoral immune responses.
Methods: We evaluated 93 paired maternal and neonatal umbilical cord blood plasma samples collected between October 2020 and February 2022 from a birth cohort of pregnant women from New Orleans, Louisiana, with histories of SARS-CoV-2 infection and/or vaccination. Plasma was profiled for the levels of spike-specific antibodies and induction of antiviral humoral immune functions, including neutralization and Fc-mediated innate immune effector functions. Responses were compared between 4 groups according to maternal infection and vaccination.
Results: We found that SARS-CoV-2 vaccination or infection during pregnancy increased the levels of antiviral antibodies compared to naive subjects. Vaccinated mothers and cord samples had the highest anti-spike antibody levels and antiviral function independent of the time of vaccination during pregnancy.
Conclusions: These results show that the most effective passive transfer of functional antibodies against SARS-CoV-2 in utero is achieved through vaccination, highlighting the importance of vaccination in pregnant women.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. Global - 3(2024), 1 vom: 25. Jan., Seite 100189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lauritsen, Cody J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 26.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jacig.2023.100189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367589621 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367589621 | ||
| 003 | DE-627 | ||
| 005 | 20240126232209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacig.2023.100189 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367589621 | ||
| 035 | |a (NLM)38268538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lauritsen, Cody J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Background: Pregnancy is associated with a higher risk of adverse symptoms and outcomes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for both mother and neonate. Antibodies can provide protection against SARS-CoV-2 infection and are induced in pregnant women after vaccination or infection. Passive transfer of these antibodies from mother to fetus in utero may provide protection to the neonate against infection. However, it is unclear whether the magnitude or quality and kinetics of maternally derived fetal antibodies differs in the context of maternal infection or vaccination | ||
| 520 | |a Objective: We aimed to determine whether antibodies transferred from maternal to fetus differed in quality or quantity between infection- or vaccination-induced humoral immune responses | ||
| 520 | |a Methods: We evaluated 93 paired maternal and neonatal umbilical cord blood plasma samples collected between October 2020 and February 2022 from a birth cohort of pregnant women from New Orleans, Louisiana, with histories of SARS-CoV-2 infection and/or vaccination. Plasma was profiled for the levels of spike-specific antibodies and induction of antiviral humoral immune functions, including neutralization and Fc-mediated innate immune effector functions. Responses were compared between 4 groups according to maternal infection and vaccination | ||
| 520 | |a Results: We found that SARS-CoV-2 vaccination or infection during pregnancy increased the levels of antiviral antibodies compared to naive subjects. Vaccinated mothers and cord samples had the highest anti-spike antibody levels and antiviral function independent of the time of vaccination during pregnancy | ||
| 520 | |a Conclusions: These results show that the most effective passive transfer of functional antibodies against SARS-CoV-2 in utero is achieved through vaccination, highlighting the importance of vaccination in pregnant women | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a antibody-dependent cellular cytotoxicity | |
| 650 | 4 | |a antibody-dependent complement activation | |
| 650 | 4 | |a antibody-dependent phagocytosis | |
| 650 | 4 | |a maternal infection | |
| 650 | 4 | |a maternal vaccination | |
| 650 | 4 | |a neutralization | |
| 650 | 4 | |a placental transfer | |
| 700 | 1 | |a Trinh, Ivy V |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Srushti P |e verfasserin |4 aut | |
| 700 | 1 | |a Clancey, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Murrell, Amelie E |e verfasserin |4 aut | |
| 700 | 1 | |a Rambaran, Saraswatie |e verfasserin |4 aut | |
| 700 | 1 | |a Chandra, Sruti |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Debra H |e verfasserin |4 aut | |
| 700 | 1 | |a Smira, Ashley R |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Zhiyin |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Addison E |e verfasserin |4 aut | |
| 700 | 1 | |a Agbodji, Ayitevi |e verfasserin |4 aut | |
| 700 | 1 | |a Dugas, Courtney M |e verfasserin |4 aut | |
| 700 | 1 | |a Satou, Ryousuke |e verfasserin |4 aut | |
| 700 | 1 | |a Pridjian, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Sherri |e verfasserin |4 aut | |
| 700 | 1 | |a Ley, Sylvia H |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Norton, Elizabeth B |e verfasserin |4 aut | |
| 700 | 1 | |a Piedimonte, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Gunn, Bronwyn M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. Global |d 2022 |g 3(2024), 1 vom: 25. Jan., Seite 100189 |w (DE-627)NLM345686632 |x 2772-8293 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2024 |g number:1 |g day:25 |g month:01 |g pages:100189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacig.2023.100189 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2024 |e 1 |b 25 |c 01 |h 100189 | ||